Andreas H. Laustsen-Kiel

Andreas H. Laustsen-Kiel is the Co-Founder and CTO at Bactolife. Prior to this, they were an advisor in the WHO Working Group on Snakebite Envenoming from November 2017 to May 2019. In this role, they developed a strategic plan for snakebite envenoming with the aim of assessing and addressing the global burden of snakebite envenoming, especially in mid- to low-income countries. Before that, Andreas was a visiting scientist at the University of Copenhagen from February 2016 to January 2017, and a visiting researcher at the University of Cambridge from January 2016 to March 2016. Andreas also founded the Copenhagen branch of Innovation Forum in May 2014 and served as its leader until August 2015. Andreas received their postdoctoral fellowship from DTU - Technical University of Denmark in June 2016 and worked there until January 2018 on recombinant antivenins against snakebite, antibody discovery, CHO cell expression, phage display, toxinology, and drug discovery.

Andreas H. Laustsen-Kiel has a Doctor of Philosophy (PhD) in Molecular and Cellular Pharmacology from Københavns Universitet, an M.Sc.Eng (Honors Program) in Advanced and Applied Chemistry from the Technical University of Denmark, and an MSc in Chimie Moléculaire from Université Pierre et Marie Curie (Paris VI). Andreas also has a certification from the University of Cambridge in Certificate of Proficiency in English.

They are on a team with Christel Jørgensen - Head, Regulatory Affairs, Sandra Wingaard Thrane - Co-Founder & SVP, Research, and Sebastian Søderberg - Chief Commercial Officer & CFO. Their manager is Mads Laustsen, Co-Founder & CEO.